Why Dyne Therapeutics, Inc.’s (DYN) Stock Is Down 12.95%

By Cynthia McLaughlin
December 09, 2025
Featured Tickers:
DYN

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Dyne Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Dyne Therapeutics, Inc.’s stock price such as:

  • Dyne Therapeutics, Inc.’s current stock price and volume
  • Why Dyne Therapeutics, Inc.’s stock price changed recently
  • Upgrades and downgrades for DYN from analysts
  • DYN’s stock price momentum as measured by its relative strength

About Dyne Therapeutics, Inc. (DYN)

Before we jump into Dyne Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Want to learn more about Dyne Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Dyne Therapeutics, Inc..

Learn More About A+ Investor

Dyne Therapeutics, Inc.’s Stock Price as of Market Close

As of December 09, 2025, 4:00 PM, CST, Dyne Therapeutics, Inc.’s stock price was $18.440.

Dyne Therapeutics, Inc. is down 16.94% from its previous closing price of $22.200.

During the last market session, Dyne Therapeutics, Inc.’s stock traded between $18.210 and $21.680. Currently, there are approximately 141.81 million shares outstanding for Dyne Therapeutics, Inc..

Dyne Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Dyne Therapeutics, Inc. Stock Price History

Dyne Therapeutics, Inc.’s (DYN) price is currently down 15.8% so far this month.

During the month of December, Dyne Therapeutics, Inc.’s stock price has reached a high of $23.960 and a low of $18.210.

Over the last year, Dyne Therapeutics, Inc. has hit prices as high as $28.960 and as low as $6.360. Year to date, Dyne Therapeutics, Inc.’s stock is down 21.73%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Dyne Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 09, 2025, there was 1 analyst who downgraded Dyne Therapeutics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Dyne Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Dyne Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Dyne Therapeutics, Inc. (DYN) by visiting AAII Stock Evaluator.

Relative Price Strength of Dyne Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 09, 2025, Dyne Therapeutics, Inc. has a weighted four-quarter relative price strength of 12.53%, which translates to a Momentum Score of 85 and is considered to be Very Strong.

Want to learn more about how Dyne Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Dyne Therapeutics, Inc. Stock Price: Bottom Line

As of December 9, 2025, Dyne Therapeutics, Inc.’s stock price is $18.440, which is down 16.94% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Dyne Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.

Learn More About A+ Investor

Find New Stock Opportunities With Included With AAII Platinum
O'Neil CAN SLIM Screen: 38.3% Compared to S&P 500
at only 23.3%

Since Inception. Data as of 12/31/2024.




Try AAII Platinum and get full access to
769.3% Stock Superstars Portfolio Total Return Since Inception
Compare to:
710.3% iShare DOW Jones
U.S. Index ETF (IYY)

SSR Group 3 O'Shaughnessy portfolio has a 411.2% gain since inception performance compared to IYY at only 119.1%% Performance as of 11/29/24.

Get your free copy of our special report analyzing the tech stocks most likely to outperform the market.

Download the FREE Report Here:

BECOME A MEMBER FOR ONLY $2

Get access to powerful investment discovery tools and a wealth of investment education to help you achieve your financial goals.